Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Testicular Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Melanoma 1Bone Neoplasms 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × Histocompatibility Testing × Clear all
NCT05819827 2025-04-27

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

Mayo Clinic

Terminated
13 enrolled
DermatologicGenitourinarySarcoma

Urinary Bladder Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡